Myeloma 2022: day one highlights
Episode 142 of the VJHemOnc Podcast podcast, hosted by VJHemOnc, titled "Myeloma 2022: day one highlights" was published on July 27, 2022 and runs 11 minutes.
July 27, 2022 ·11m · VJHemOnc Podcast
Summary
At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety of topics, including novel targets, T-cell engager therapy, myeloma at the single-cell level, the role of measurable residual disease (MRD), and more. Leading experts came together to discuss, debate, and answer questions, bringing you the latest in the field. In this exclusive podcast, Keith Stewart, MB, ChB, Princess Margaret Cancer Centre, Toronto, Canada, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, and Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone, New York, NY, share some key highlights from day one at this year's meeting. The experts talk on updates in MRD and prognosis, antibody therapy for amyloidosis, and more.
Episode Description
At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety of topics, including novel targets, T-cell engager therapy, myeloma at the single-cell level, the role of measurable residual disease (MRD), and more. Leading experts came together to discuss, debate, and answer questions, bringing you the latest in the field.
In this exclusive podcast, Keith Stewart, MB, ChB, Princess Margaret Cancer Centre, Toronto, Canada, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, and Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone, New York, NY, share some key highlights from day one at this year's meeting. The experts talk on updates in MRD and prognosis, antibody therapy for amyloidosis, and more.
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.